Yüklüyor......
An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
PURPOSE: Glasdegib, an oral inhibitor of the Hedgehog signaling pathway, is approved in the United States in combination with low-dose cytarabine (LDAC) to treat patients with newly diagnosed acute myeloid leukemia (AML) ineligible to receive intensive chemotherapy. This population pharmacokinetic/p...
Kaydedildi:
| Yayımlandı: | Cancer Chemother Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer Berlin Heidelberg
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7515941/ https://ncbi.nlm.nih.gov/pubmed/32885274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04132-x |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|